{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696821,"version":"4.6.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tislelizumab is an anti-programmed cell death protein 1(anti-PD-1) monoclonal antibody, which was approved by the Food and Drug Administration(FDA) on March 14, 2024. However, clinical studies are often limited by small sample sizes, and thus a more comprehensive evaluation of the safety of Tislelizumab, particularly its immune-related adverse reactions, is urgently needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Disproportionality analysis was used in this study to assess the safety of Tislelizumab in clinical practice by analyzing all adverse event reports from the FDA Adverse Event Reporting System database, starting from the first quarter of 2024, where Tislelizumab was identified as the primary suspected drug. Two disproportionality analysis methods, reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN), were utilized to investigate the adverse reactions related to Tislelizumab. Additionally, the Weibull distribution was employed to examine the time-dependent changes in the incidence of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Consistent with the drug label, this study identified significant positive signals for adverse reactions, including myelosuppression, hepatic dysfunction, pruritus, rash, and exfoliative dermatitis. Notably, this study also identified several adverse reactions not documented in the drug label, including palmar-plantar erythrodysaesthesia syndrome, immune-mediated cystitis, and renal cysts. Adverse reactions associated with Tislelizumab generally manifested within the first month of treatment. In terms of immune-related adverse reactions, Tislelizumab demonstrated lower signal values compared to other immune checkpoint inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study comprehensively reviews the safety profile of Tislelizumab, thereby providing clinicians with crucial safety information for prescribing this drug. Due to its relatively low risk of immune-related adverse events (irAEs), Tislelizumab may serve as a promising candidate for combination therapy with other immune checkpoint inhibitors (ICIs). Novel combination strategies involving Tislelizumab and other ICIs are anticipated to provide new therapeutic opportunities for patients experiencing irAEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1596842","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:17:32Z","timestamp":1748236652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Chen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"108720","DOI":"10.1016\/j.cbi.2019.06.033","article-title":"Emerging trends in the novel drug delivery approaches for the treatment of lung cancer","volume":"309","author":"Sharma","year":"2019","journal-title":"Chem Biol Interact"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","article-title":"Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12885-024-11919-1","article-title":"The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12890-023-02755-3","article-title":"The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials","volume":"23","author":"Daei Sorkhabi","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): A phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e000866","DOI":"10.1136\/esmoopen-2020-000866","article-title":"Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors","volume":"5","author":"Anand","year":"2020","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02568-y","article-title":"Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States","volume":"42","author":"Yang","year":"2023","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000437","DOI":"10.1136\/jitc-2019-000437","article-title":"Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1\/2 study","volume":"8","author":"Shen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fimmu.2022.1085057","article-title":"Drug-induced liver injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/tx700186p","article-title":"Idiosyncratic drug reactions: past, present, and future","volume":"21","author":"Uetrecht","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatol Baltim Md"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1226993","article-title":"Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis\/cystitis and review of the literature","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501415","article-title":"Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis\/cystitis treated by ureteral stent and review of the literature","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051577","article-title":"Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e161318","DOI":"10.1172\/jci.insight.161318","article-title":"Immune checkpoint activity regulates polycystic kidney disease progression","volume":"8","author":"Kleczko","year":"2023","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771335","article-title":"Various uses of PD1\/PD-L1 inhibitor in oncology: opportunities and challenges","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02128-3","article-title":"A Phase 1\/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours","volume":"128","author":"Desai","year":"2023","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T05:17:33Z","timestamp":1748236653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1596842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2025.1596842"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1596842","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1596842"}}